Sun Pharmaceutical Industries stock

SUNPHARMA · NSE · INR

Compare Sun Pharmaceutical Industries
₹1,880.00Change from previous close: −0.27%Absolute change: −₹5.00

Close · November 13, 2026

Price history

+8.21% over the period

1 year: from ₹1,737.40 (November 13, 2025) to ₹1,880.00 (November 13, 2026), +8.21%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026₹1,880.00
October 30, 2026₹1,777.70
September 30, 2026₹1,816.60
August 31, 2026₹1,984.80
July 31, 2026₹1,990.50
June 30, 2026₹1,862.50
May 29, 2026₹1,799.20
April 30, 2026₹1,808.30
March 30, 2026₹1,757.20
February 27, 2026₹1,737.00
January 30, 2026₹1,595.30
December 31, 2025₹1,719.70
November 28, 2025₹1,831.60
November 13, 2025₹1,737.40

At a glance

  • The company

    Generic pharmaceutical company developing, manufacturing and marketing branded and generic formulations and active pharmaceutical ingredients across multiple therapeutic areas

  • Latest results

    Quarter to September 30, 2026 · EPS ₹13.16 (estimate ₹12.89)

TickerLandia's take on Sun Pharmaceutical Industries

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low₹1,583.70
52-wk high₹2,046.90

−8.15% from the 52-week high

Analysts · 34 analysts

Average target₹2,111.94+12.34% vs. price

Buy 29 · Hold 1 · Sell 4 · Buy

TickerLandia Fingerprint: Sun Pharmaceutical Industries

Compared with similar companies: very low risk.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Sun Pharmaceutical Industries is priced as in the past and in line with similar companies

On the latest fiscal year's earnings (2026), Sun Pharmaceutical Industries's P/E today is 39.3, in line with the median of its last 10 fiscal years (39.3; between 22.5 and 67.3 from 2017 to 2026). Sun Pharmaceutical Industries's P/E (trailing 12 months): 40.9, in line with the median of a group of 11 similar companies (40.9).

P/E compared with its history

Compared with 11 similar companies

Sun Pharmaceutical Industries's metrics compared with similar companies
MetricSun Pharmaceutical IndustriesPosition in the groupBand
P/E (trailing 12 months)40.9Middle
Forward P/E29.7Middle
Operating margin23.3%Middle
ROE13.1%Low
Debt/equity0.04Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Sun Pharmaceutical Industries. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

₹161.99B

Latest quarter · Q3 2026

Net income

₹19.89B

Latest quarter · Q3 2026

Quarterly net margin

12.3%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
₹4.48T
P/E
40.9
EPS
₹45.70
Volume
1.3M
Daily trading
€40.54M
Dividend yield
0.85%
Last ex-dividend on July 7, 2026

How Sun Pharmaceutical Industries is changing

All results
  • Revenue grew 11.8% a year on average over the last 5 years

  • Operating margin rose from 21.2% to 23.3%

  • Profits turn into cash: free cash flow equal to 96% of net income

Returns

Sun Pharmaceutical Industries returns with dividends

₹1,000 invested in Sun Pharmaceutical Industries 5 years ago, on November 15, 2021, would be worth ₹2,436 today with dividends reinvested: +143.57% in total, +19.51% per year. On price alone it would be ₹2,319 (+131.90%).

PeriodSun Pharmaceutical Industries₹1,000 becomes
1 month+6.17%₹1,062
6 months+3.02%₹1,030
Year to date+9.32%₹1,093
1 year+9.19%₹1,092
3 years+63.99%₹1,640
5 years+143.57%₹2,436
10 years+200.23%₹3,002

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Sun Pharmaceutical Industries: technical analysis

Sun Pharmaceutical Industries shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 6.1% below its all-time closing high (₹2,001.10, July 30, 2026).

Trend
No clear trend
RSI (14 sessions)
64
Between 30 and 70
vs 200-session average
+3.19%

Active signals

  • Death cross: the 50-session average has crossed below the 200-session average.

    since November 11, 2026

Support and resistance

Price areas where Sun Pharmaceutical Industries has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance₹1,903.50+1.25%3 touches, last on September 21, 2026
  2. Last price₹1,880.00
  3. Support₹1,846.00−1.81%2 touches, last on March 11, 2026
  4. Support₹1,817.87−3.30%3 touches, last on September 15, 2026
  5. Support₹1,754.20−6.69%3 touches, last on June 3, 2026

Volatility and risk

Volatility (60 sessions, annualised)
18.7%
Largest fall in the last year
−13.23%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Sun Pharmaceutical Industries: seasonality

Average monthly price change over 31 years

+2.0%Jan+2.8%Feb+4.1%Mar+3.0%Apr−0.2%May+1.6%Jun+5.3%Jul+3.9%Aug+2.4%Sep+0.7%Oct+2.2%Nov+1.5%Dec

Over the last 31 years, the strongest month for Sun Pharmaceutical Industries has been July: +5.34% on average, positive in 24 years out of 31. The weakest has been May: −0.19% on average, positive in 14 years out of 31. November, the current month, has been positive in 18 years out of 30 (+2.20% on average).

Show chart data
MonthAverageMedianPositive years
January+1.98%+1.25%18 of 30
February+2.78%+1.13%17 of 31
March+4.14%+2.09%21 of 31
April+2.98%+2.91%22 of 31
May−0.19%−1.25%14 of 31
June+1.56%+0.05%16 of 31
July+5.34%+6.43%24 of 31
August+3.90%+1.34%17 of 31
September+2.41%+1.17%19 of 31
October+0.67%−0.20%15 of 31
November+2.20%+2.56%18 of 30
December+1.52%+2.76%17 of 30

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Sun Pharmaceutical Industries and its competitors

Its tablets, capsules, injectables, inhalers and creams reach patients through a portfolio spanning neuropsychiatry, cardiology, diabetes, gastroenterology and oncology, among other areas. Alongside prescription medicines, the group sells over-the-counter vitamins, analgesics and digestive products, as well as antiretroviral drugs, peptides and steroids. It also supplies active pharmaceutical ingredients and generics for anti-cancer, immunosuppressant and controlled-substance medicines, with operations in India, the United States and other international markets.

Headquarters
Mumbai, India
Employees
47,000
Founded
1983
Chief executive
Kirti Ganorkar
Sun Pharmaceutical Industries and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Sun Pharmaceutical IndustriesSUNPHARMA$47.94B23.3%40.9+3.02%
Jiangsu Hengrui Pharmaceuticals600276$47.86B27.4%35.9−11.86%
Takeda Pharmaceutical4502$65.79B16.6%253.2+31.34%
Divi's LaboratoriesDIVISLAB$31.67B34.0%88.0+64.93%
Hansoh Pharmaceutical Group3692$25.82B37.3%27.6−5.09%
Torrent PharmaceuticalsTORNTPHARM$19B22.2%78.9+5.97%

Same industry or related industries, similar size. Compare Sun Pharmaceutical Industries with its competitors · Full profile